UNASSIGNED: 713 Background: In @entity0 @entity1 with bony @entity3 @entity5520 therapy is established to be of benefit in reducing the skeletal related events (SRE's). It is not known whether the postmenopausal or the premenopausal @entity1 benefit more. This study was done to assess the implication of menopausal status modifying the SRE's and response to @entity19160 (Bonefos) therapy. METHODS: Fifty @entity0 @entity1 with metastatic @entity79 categorised in two groups were followed up on @entity19160 therapy over one year for SRE's. Group A constituting twenty-five pre and Group B twenty-five @entity0 @entity1 . @entity1 with the visceral spread, @entity625 , @entity170 , hormone therapy and less than one year since last menstrual cycle were excluded. Intravenous infusion of @entity19160 1500mg was given at monthly intervals. @entity1 were followed up at monthly interval with emphasis on history and scoring for @entity158 , radiographic studies when required and check for serum @entity460 level. Isotope bone scanning and radiological survey was done on initial diagnosis, at six months and end of one year. RESULTS: Forty-two @entity1 were available for evaluation completing one year on therapy. In twenty evaluable in Group A, eight complained of @entity158 and two of them had pathological @entity174 and were given radiation. In the rest of six two had significant @entity158 relief (> 50% on @entity158 score) with @entity19160 , while four required radiotherapy for @entity158 control. In Group B, twenty two evaluated for SRE's, four had pathological @entity174 and @entity158 thus requiring radiation. Twelve complained of @entity158 only with two requiring radiotherapy to relieve @entity158 and remaining ten had significant @entity158 relief with @entity19160 therapy. @entity2741 was seen in one in group A and three in group B before beginning of therapy, all became normocalcemic with single infusion of @entity19160 . CONCLUSIONS: In a follow up of one year @entity0 @entity1 with bony @entity3 have higher rate of SRE's and tend to benefit more than in premenopausal @entity1 with @entity19160 therapy. No significant financial relationships to disclose.

Skeletal related events in XXXX @entity1 with metastatic @entity79 .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity0 :: ('MESH:D001943', 'Disease') :: ['postmenopausal breast cancer', 'breast cancer'] @entity625 :: ('MESH:D001168', 'Disease') :: ['arthritis'] @entity174 :: ('MESH:D050723', 'Disease') :: ['fracture'] @entity2741 :: ('MESH:D006934', 'Disease') :: ['Hypercalcemia'] @entity170 :: ('MESH:D010024', 'Disease') :: ['osteoporosis'] @entity5520 :: ('D004164', 'Chemical') :: ['Bisphosphonate'] @entity79 :: ('MESH:D001847', 'Disease') :: ['bone disease'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis'] @entity158 :: ('MESH:D010146', 'Disease') :: ['skeletal pain', 'pain'] @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium'] @entity19160 :: ('MESH:D004002', 'Chemical') :: ['Clodronate']
@entity0 :: (MESH:D001943,Disease) :: ['breast cancer']
